Medpace Holdings, Inc. (MEDP)
NASDAQ: MEDP · Real-Time Price · USD
337.28
+2.13 (0.64%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.

Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc.
Medpace Holdings logo
Country United States
Founded 1992
IPO Date Aug 11, 2016
Industry Diagnostics & Research
Sector Healthcare
Employees 5,900
CEO August Troendle

Contact Details

Address:
5375 Medpace Way
Cincinnati, Ohio 45227
United States
Phone 513 579 9911
Website medpace.com

Stock Details

Ticker Symbol MEDP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001668397
CUSIP Number 58506Q109
ISIN Number US58506Q1094
Employer ID 32-0434904
SIC Code 8731

Key Executives

Name Position
Dr. August James Troendle M.D. Chairman and Chief Executive Officer
Jesse J. Geiger BBA, CPA President
Kevin M. Brady Chief Financial Officer and Treasurer
Susan E. Burwig BSN, MA Executive Vice President of Operations
Stephen P. Ewald J.D. Chief Compliance Officer, General Counsel and Corporate Secretary
Brandon Ebken Chief Information Officer
Lauren Morris Associate Director of Investors Relations
Todd Meyers Vice President of Business Development and Marketing
John T. Wynne MBA Senior Vice President of Commercial Operations and Clinical Pharmacology Unit
Reinilde Heyrman M.D. Chief Medical Officer of Medical Department

Latest SEC Filings

Date Type Title
Oct 22, 2024 10-Q Quarterly Report
Oct 21, 2024 8-K Current Report
Aug 23, 2024 144/A Filing
Aug 22, 2024 144 Filing
Aug 16, 2024 144 Filing
Aug 15, 2024 144 Filing
Aug 9, 2024 144 Filing
Aug 6, 2024 144 Filing
Jul 30, 2024 144 Filing
Jul 25, 2024 144 Filing